Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Neurological Biomarkers Market Size Outlook: How Fast Will Revenue Grow Through 2030?
Neurological biomarkers experienced a substantial expansion recently, with projections indicating a rise from $11.92 billion in 2025 to $13.52 billion in 2026, representing a compound annual growth rate of 13.4%. This historical growth trajectory is underpinned by several key factors, including the escalating incidence of neurological conditions, advancements in the early identification of protein biomarkers, a surge in the application of imaging biomarkers, the increasing integration of DNA biomarkers, and the nascent incorporation of biomarkers within clinical trial frameworks.
The neurological biomarkers sector is poised for substantial expansion over the upcoming years, projected to reach a market value of $22.82 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.0%. This anticipated growth is fueled by several key factors: the broadening application of personalized medicine utilizing biomarkers, an escalating demand for metabolomic biomarkers, augmented investment in central nervous system (CNS) drug development, advancements in cutting-edge diagnostic platforms, and the increasing deployment of biomarker-guided disease monitoring strategies. Significant trends anticipated within this forecast period include the growing utilization of biomarkers for the early detection of neurological conditions, a heightened adoption rate of proteomic and genomic biomarkers, the expanded use of imaging biomarkers in assessing CNS disorders, a surge in demand for biomarkers throughout drug development pipelines, and a heightened clinical emphasis on testing for biomarkers associated with neurodegenerative diseases.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp
Neurological Biomarkers Market Growth Factors Supporting Long-Term Expansion
The rising incidence of conditions affecting the nervous system is anticipated to drive the expansion of the neurological biomarker market. Neurological disorders encompass a range of ailments impacting the brain, spinal cord, and peripheral nerves. Parkinson’s disease, a prime example of a neurodegenerative condition, specifically targets the nervous system and the bodily functions it governs. Neurological biomarkers play a crucial role in the early detection of Parkinson’s disease through methods including pathological, biochemical, and genetic analyses. Evidence from October 2023, as reported by the World Federation of Neurology, highlights a significant and escalating global health challenge, with neurological disorders now identified as the second-highest cause of mortality and the foremost contributor to disability worldwide; by 2023, over 40 percent of the global populace experienced such conditions, and projections indicate that the number of individuals living with brain diseases will nearly double by the year 2050. Consequently, the growing number of neurological diseases is a key factor fueling the neurological biomarker market’s growth.
Neurological Biomarkers Market Segmentation: How Is The Market Structured Across Key Categories?
The neurological biomarkers market covered in this report is segmented –
1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users
Subsegments:
1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers
2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers
3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers
4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers
5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers
Neurological Biomarkers Market Industry Trends Shaping Future Revenue Growth
In the realm of neurological biomarkers, leading entities are actively innovating, notably by introducing novel blood tests for biomarkers to enhance their market standing. These sophisticated blood tests are designed to scrutinize particular molecules within the bloodstream, thereby offering insights into an individual’s health status, the presence of diseases, or ongoing physiological functions. A prime illustration of this trend occurred in July 2023 when Quanterix Corporation, a United States firm renowned for its cutting-edge digital immunoassay platforms, unveiled its LucentAD biomarker blood test. This diagnostic tool is specifically engineered to aid healthcare providers in assessing individuals exhibiting cognitive difficulties suggestive of early-stage Alzheimer’s disease. The LucentAD test measures p-Tau 181 concentrations, a known indicator of the pathological processes associated with Alzheimer’s disease. When an adult presents with cognitive impairment and is undergoing evaluation for AD 1, the results from the LucentAD test serve as a valuable component of the diagnostic process. It is crucial to note that this test is not intended for use as an independent screening or diagnostic method; rather, it functions most effectively when integrated with other established diagnostic procedures.
Neurological Biomarkers Market Competitive Landscape And Leading Companies
Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.
Access The Complete Neurological Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Neurological Biomarkers Market Geographic Analysis: Where Is Demand Growing The Fastest?
North Americawas the largest region in the neurological biomarkers market in 2025. The regions covered in the neurological biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
